Patel K R, Al Shama M R, Kerr J W
Clin Allergy. 1983 Mar;13(2):119-22. doi: 10.1111/j.1365-2222.1983.tb02578.x.
In eight patients with extrinsic bronchial asthma the effect of inhaled verapamil (3 and 6 mg) was compared with saline on bronchial challenge with extracts of Dermatophagoides pteronyssinus. There was no significant difference in the baseline FEV1 before and after inhalation of saline or verapamil 2.5 mg/ml. However, verapamil at a higher concentration (5 mg/ml) caused bronchoconstriction in four patients who had to be excluded from the part of the study. Verapamil at both these concentrations failed to have an effect on the allergen-induced bronchoconstriction. These findings suggest that verapamil given by inhalation does not prevent mediator release from the lung mast cells following specific allergen challenge.
在8例外源性支气管哮喘患者中，比较了吸入维拉帕米（3毫克和6毫克）与生理盐水对用尘螨提取物进行支气管激发试验的影响。吸入生理盐水或2.5毫克/毫升维拉帕米前后的基线第一秒用力呼气量（FEV1）无显著差异。然而，较高浓度（5毫克/毫升）的维拉帕米在4例患者中引起了支气管收缩，这4例患者不得不被排除在研究的该部分之外。这两种浓度的维拉帕米均未能对变应原诱导的支气管收缩产生影响。这些发现表明，吸入维拉帕米不能阻止特异性变应原激发后肺肥大细胞释放介质。
